Thus, our data indicate that the NANOG-CD59 axis responsible for the CDC-refractory property is conserved across multiple types of cancer cells, and that inhibition of NANOG, as part of an antibody-based therapy, represents an attractive strategy for the control of CDC-refractory cancer. This evidence concerns the gene NANOG and cancer.